Headlines
-
ASCO 2020 – New regimen yields better adherence, less toxicity in head and neck SCC First hints of noninferiority for chemoradiotherapy weekly vs q3w in high-risk, post-op patients.
-
ASCO 2020 – Metastatic NSCLC: no clear benefit with chemo add-on to durvalumab+tremelimumab Addition of platinum-based regimen yielded no OS improvement.
-
ASCO 2020 – eRAPID, a new model of care that improves physical well-being during chemotherapy Telemedicine acquires special value in light of the COVID-19 pandemic.
